 Connection
Lisa Bero to United States Food and Drug Administration
This is a "connection" page, showing publications Lisa Bero has written about United States Food and Drug Administration.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.865 |
|
|
|
-
Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf. 2009; 32(11):1057-66.
Score: 0.295
-
Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008 Nov 25; 5(11):e217; discussion e217.
Score: 0.293
-
Nguyen NT, Cook DM, Bero LA. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study. Clin Ther. 2006 Aug; 28(8):1231-1243.
Score: 0.249
-
Roth AL, Dunsby J, Bero LA. Framing processes in public commentary on US federal tobacco control regulation. Soc Stud Sci. 2003 Feb; 33(1):7-44.
Score: 0.196
-
Stryer D, Bero LA. Characteristics of materials distributed by drug companies. An evaluation of appropriateness. J Gen Intern Med. 1996 Oct; 11(10):575-83.
Score: 0.126
-
Schroll J, Bero L. Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev. 2015 Apr 20; 4:ED000098.
Score: 0.114
-
Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol. 2015 Jan; 68(1):102-7.
Score: 0.109
-
Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med. 2013 Dec 9-23; 173(22):2032-6.
Score: 0.104
-
Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012 Jan 03; 344:d7202.
Score: 0.091
-
Dhruva SS, Bero LA, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011 Mar; 4(2):165-71.
Score: 0.086
-
Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009 Dec 23; 302(24):2679-85.
Score: 0.079
-
White J, Parascandola M, Bero L. Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. Nicotine Tob Res. 2007 Nov; 9(11):1213-25.
Score: 0.068
-
Chang L, Dhruva SS, Chu J, Bero LA, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ. 2015 Jun 10; 350:h2613.
Score: 0.029
-
Stryer DB, Bero LA. Drug promotion. N Engl J Med. 1995 Apr 13; 332(15):1032; author reply 1033.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|